Antoni Ribas
Antoni Ribas
Verified email at
Cited by
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
PD-1 blockade induces responses by inhibiting adaptive immune resistance
PC Tumeh, CL Harview, JH Yearley, IP Shintaku, EJM Taylor, L Robert, ...
Nature 515 (7528), 568-571, 2014
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
Cancer immunotherapy using checkpoint blockade
A Ribas, JD Wolchok
Science 359 (6382), 1350-1355, 2018
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
Primary, adaptive, and acquired resistance to cancer immunotherapy
P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas
Cell 168 (4), 707-723, 2017
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
New England Journal of Medicine 369 (2), 134-144, 2013
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
ME Davis, JE Zuckerman, CHJ Choi, D Seligson, A Tolcher, CA Alabi, ...
Nature 464 (7291), 1067-1070, 2010
Improved overall survival in melanoma with combined dabrafenib and trametinib
C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ...
New England Journal of Medicine 372 (1), 30-39, 2015
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
M Ayers, J Lunceford, M Nebozhyn, E Murphy, A Loboda, DR Kaufman, ...
The Journal of clinical investigation 127 (8), 2930-2940, 2017
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation
R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ...
Nature 468 (7326), 973-977, 2010
Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib
JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ...
New England Journal of Medicine 366 (8), 707-714, 2012
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ...
New England Journal of Medicine 371 (20), 1867-1876, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ...
The Lancet 384 (9948), 1109-1117, 2014
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
The system can't perform the operation now. Try again later.
Articles 1–20